Recipient organisationNewcastle UniversitySource-published name: Newcastle University
Funding£1.3M
PeriodJan 2024 — Dec 2027
In plain English
AI plain-English summary
A new digital platform will pull together patient data from registries, wearable devices, and patient-reported experiences into a single, integrated system for neuromuscular diseases. This matters because patient data is currently scattered across different sources—clinical registries, fitness trackers, symptom diaries, and regulatory databases—making it difficult to use for clinical trials, treatment decisions, or drug development. The Interactium platform aims to align all this data at the individual patient level, giving patients control over their own information while providing researchers, clinicians, and regulators with a holistic view of disease progression and treatment effects. If successful, the system could speed up clinical trial recruitment, improve regulatory decision-making, and help patients and doctors make better-informed treatment choices. The platform is being built for neuromuscular diseases first—where patient groups are well-defined and research is active—but the architecture is designed to scale to common conditions like diabetes. The project will also produce standard operating procedures and a toolkit for rare disease organisations, allowing other disease areas to build similar systems without starting from scratch.
View original technical description
Neuromuscular disease is at the forefront of collecting real-world demographic and clinically-relevant data from patients. PaLaDIn, a public private partnership, will leverage TREAT-NMD's Global Registry Platform. This uses patient data to support clinical trial planning/ recruitment as well as more complex regulator-driven studies. With other Partners’ expertise in patient engagement and FAIR data, this a public private partnership, will develop the Interactium, a new, integrated approach to patient data. The Interactium will align registry-reported data with Patient Reported Outcome/Experience Measures and other data e.g., wearables and Internet of Things devices, and share the collated, holistic data to improve outcomes and decision-making, and accelerate innovation for a range of stakeholders (patients, regulators, industry and initiatives like DARWIN). PaLaDIn’s other objectives: • Develop a patient interface to collect patient preferences to support an inclusive approach, and to allow visualization of data and control over its use. • Provide class-leading tools to support all stages of decision-making in translational research, care and diagnosis across the neuromuscular field and develop Standard Operating Procedures to allow utilization across the rare disease and wider health fields. • To provide communications and shared learning outside the neuromuscular disease field to support scale-up development of similar systems and capabilities across all diseases. Developing a patient-centric and cost-effective advanced integrated healthcare solution requires well defined patient groupsin significant, but manageable numbers, extensive ongoing research and trials and drugs at all stages of development. Neuromuscular diseases provides all of these; however, the Interactium and associated processes and frameworks have much wider potential. A system that can ingest data from any relevant source, align that data at patient level, and provide data analysis to support decision-making by patients, clinicians, regulators and health-related industries is equally relevant to more common diseases such as diabetes. PaLaDIn key deliverables • Flexible Interactium omni data platform • Architecture/template for an improved user experience • Architecture for wearable infrastructure • Novel methods for FAIRification process • Toolkit for rare disease patient organisations.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know